Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
DNAPrint Genomics, Inc. (DNAG)
Sarasota, US
DNAPrint Genomics, Inc. focuses on pioneering and distributing genetic analysis solutions and services. Their product portfolio includes AncestryByDNA, a comprehensive chromosomal assay for tracing genetic lineage, and EurasianDNA, designed to identify specific European ancestral subdivisions. They also offer EuropeanDNA, which outlines an individual's fundamental continental European heritage. In forensic science, DNAWitness assists in determining genetic background from crime scene samples, while RETINOME is utilized by detectives to construct physical traits, such as eye color, from DNA evidence or human remains. Furthermore, the company provides the GenomeLab SNPstream Genotyping System, recognized for its high genotyping throughput, multiplexing capabilities, and efficient reagent usage. DNAPrint Genomics caters to diverse clients in fields like forensic investigation, genealogical exploration, consumer products, and pharmaceutical research. Originally incorporated in 1983 as Lexington Energy, Inc., the company operates from Sarasota, Florida, with an international presence through a subsidiary in Leverkusen, Germany.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +100.00% | +100.00% | +100.00% | +100.00% | +100.00% | +1,900.00% | -98.00% | -98.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%+90.8% ★ Q3'07: -65.1% (vs Q3'06)
-
EPS growth Biotechnology: +29.7%+66.7% ★ Q3'07: +70.0% (vs Q3'06)
-
FCF margin FCF growth · Biotechnology: +16.2%-286.5% Q3'07: -599.1% (vs Q3'06)
-
EBIT margin Biotechnology: +0.0%-364.5% Q3'07: -730.6% (vs Q3'06)
-
ROIC Biotechnology: -16.1%—
-
Share dilution Biotechnology: -3.4%+290.5% Q3'07: +60.6% (vs Q3'06)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.82× Q3'07: -0.88× (vs Q3'06)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2007-04-27 | GABRIEL RICHARD L | Director / Officer | A-Award | A | Options | 20,000,000 | 0.01 | 200.0K | 40,500,000 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Emanuela Charlton | Executive Officer | — | female |
| Hector de Jesus Ruiz | Executive Officer | — | — |
| Jatin Patel | Executive Officer | — | male |
| Laurence A. Rubin | Executive Officer | — | — |
| Lisa Tandy Herren | Executive Officer | — | female |
| Naz Jiwani | Executive Officer | — | male |
| Pauline Gula | Executive Officer | — | female |
| Scot Alic | Executive Officer | — | male |
| Shannon Boyd | Executive Officer | — | male |
| Zach Gaskin | Executive Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DNAG
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
